Welcome to Barron's Advisor! Our articles are free to Barron's subscribers and wealth management professionals. To subscribe ...
Palantir stock is down 20% in 2026 as investors worry AI could disrupt software names. This firm remains bullish on Palantir.
Eli Lilly is in focus following the launch of its Foundayo pill, as investors wait to see if the drugmaker can claw back ...
Palantir stock is down 20% in 2026 as investors worry AI could disrupt software names. This firm remains bullish on Palantir.
Merrill financial advisor Michael Duckworth leads a team specializing in serving families with complex wealth and health ...
Michael Collins created fake businesses and bogus invoices to fund a lavish lifestyle that included more than 150 airplane tickets.
Trade Desk stock may be next in line for a short squeeze, spurred by Wall Street’s worries about slowing advertising spending ...
Shares of QXO have tumbled nearly 15% this week, following news that the company planned to buy insulation distributor and ...
MaxLinear, the optical-networking company, is getting priced like an artificial-intelligence play after its latest earnings ...
In our latest Big Money poll, professional investors sees meager gains for the S&P 500 this year. Here’s where they’re ...
Organon stock is rising once more on a report that the acquisition bid for the women’s healthcare company has gone up.
People currently in their 20s are likely facing a 60-year career because of longevity and rising living costs. In the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results